BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 29850623)

  • 1. Analysis of ROR1 Protein Expression in Mice with Reconstituted Human Immune System Components.
    Leung CS
    J Immunol Res; 2018; 2018():2480931. PubMed ID: 29850623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ROR1 can interact with TCL1 and enhance leukemogenesis in Eμ-TCL1 transgenic mice.
    Widhopf GF; Cui B; Ghia EM; Chen L; Messer K; Shen Z; Briggs SP; Croce CM; Kipps TJ
    Proc Natl Acad Sci U S A; 2014 Jan; 111(2):793-8. PubMed ID: 24379361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor.
    Hudecek M; Schmitt TM; Baskar S; Lupo-Stanghellini MT; Nishida T; Yamamoto TN; Bleakley M; Turtle CJ; Chang WC; Greisman HA; Wood B; Maloney DG; Jensen MC; Rader C; Riddell SR
    Blood; 2010 Nov; 116(22):4532-41. PubMed ID: 20702778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation.
    Yu J; Chen L; Cui B; Widhopf GF; Shen Z; Wu R; Zhang L; Zhang S; Briggs SP; Kipps TJ
    J Clin Invest; 2016 Feb; 126(2):585-98. PubMed ID: 26690702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of the receptor tyrosine kinase-like orphan receptor 1 (ROR1) as a diagnostic tool in chronic lymphocytic leukemia (CLL).
    Uhrmacher S; Schmidt C; Erdfelder F; Poll-Wolbeck SJ; Gehrke I; Hallek M; Kreuzer KA
    Leuk Res; 2011 Oct; 35(10):1360-6. PubMed ID: 21531460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ROR1 is expressed on hematogones (non-neoplastic human B-lymphocyte precursors) and a minority of precursor-B acute lymphoblastic leukemia.
    Broome HE; Rassenti LZ; Wang HY; Meyer LM; Kipps TJ
    Leuk Res; 2011 Oct; 35(10):1390-4. PubMed ID: 21813176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a.
    Fukuda T; Chen L; Endo T; Tang L; Lu D; Castro JE; Widhopf GF; Rassenti LZ; Cantwell MJ; Prussak CE; Carson DA; Kipps TJ
    Proc Natl Acad Sci U S A; 2008 Feb; 105(8):3047-52. PubMed ID: 18287027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy.
    Daneshmanesh AH; Mikaelsson E; Jeddi-Tehrani M; Bayat AA; Ghods R; Ostadkarampour M; Akhondi M; Lagercrantz S; Larsson C; Osterborg A; Shokri F; Mellstedt H; Rabbani H
    Int J Cancer; 2008 Sep; 123(5):1190-5. PubMed ID: 18546292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post-translational modifications regulate signalling by Ror1.
    Kaucká M; Krejčí P; Plevová K; Pavlová S; Procházková J; Janovská P; Valnohová J; Kozubík A; Pospíšilová S; Bryja V
    Acta Physiol (Oxf); 2011 Nov; 203(3):351-62. PubMed ID: 21481194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy.
    Zhang S; Cui B; Lai H; Liu G; Ghia EM; Widhopf GF; Zhang Z; Wu CC; Chen L; Wu R; Schwab R; Carson DA; Kipps TJ
    Proc Natl Acad Sci U S A; 2014 Dec; 111(48):17266-71. PubMed ID: 25411317
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Rassenti LZ; Balatti V; Ghia EM; Palamarchuk A; Tomasello L; Fadda P; Pekarsky Y; Widhopf GF; Kipps TJ; Croce CM
    Proc Natl Acad Sci U S A; 2017 Oct; 114(40):10731-10736. PubMed ID: 28923920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sleeping Beauty Transposition of Chimeric Antigen Receptors Targeting Receptor Tyrosine Kinase-Like Orphan Receptor-1 (ROR1) into Diverse Memory T-Cell Populations.
    Deniger DC; Yu J; Huls MH; Figliola MJ; Mi T; Maiti SN; Widhopf GF; Hurton LV; Thokala R; Singh H; Olivares S; Champlin RE; Wierda WG; Kipps TJ; Cooper LJ
    PLoS One; 2015; 10(6):e0128151. PubMed ID: 26030772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia.
    Baskar S; Kwong KY; Hofer T; Levy JM; Kennedy MG; Lee E; Staudt LM; Wilson WH; Wiestner A; Rader C
    Clin Cancer Res; 2008 Jan; 14(2):396-404. PubMed ID: 18223214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia.
    Cui B; Ghia EM; Chen L; Rassenti LZ; DeBoever C; Widhopf GF; Yu J; Neuberg DS; Wierda WG; Rai KR; Kay NE; Brown JR; Jones JA; Gribben JG; Frazer KA; Kipps TJ
    Blood; 2016 Dec; 128(25):2931-2940. PubMed ID: 27815263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignancies.
    Daneshmanesh AH; Porwit A; Hojjat-Farsangi M; Jeddi-Tehrani M; Tamm KP; Grandér D; Lehmann S; Norin S; Shokri F; Rabbani H; Mellstedt H; Österborg A
    Leuk Lymphoma; 2013 Apr; 54(4):843-50. PubMed ID: 22988987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term human CD34+ stem cell-engrafted nonobese diabetic/SCID/IL-2R gamma(null) mice show impaired CD8+ T cell maintenance and a functional arrest of immature NK cells.
    André MC; Erbacher A; Gille C; Schmauke V; Goecke B; Hohberger A; Mang P; Wilhelm A; Mueller I; Herr W; Lang P; Handgretinger R; Hartwig UF
    J Immunol; 2010 Sep; 185(5):2710-20. PubMed ID: 20668220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-transplantation of human fetal thymus, bone and CD34(+) cells into young adult immunodeficient NOD/SCID IL2Rγ(null) mice optimizes humanized mice that mount adaptive antibody responses.
    Chung YS; Son JK; Choi B; Joo SY; Lee YS; Park JB; Moon H; Kim TJ; Kim SH; Hong S; Chang J; Kang MS; Kim SJ
    Clin Immunol; 2015 Apr; 157(2):156-65. PubMed ID: 25725428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spontaneous Immunity Against the Receptor Tyrosine Kinase ROR1 in Patients with Chronic Lymphocytic Leukemia.
    Hojjat-Farsangi M; Jeddi-Tehrani M; Daneshmanesh AH; Mozaffari F; Moshfegh A; Hansson L; Razavi SM; Sharifian RA; Rabbani H; Österborg A; Mellstedt H; Shokri F
    PLoS One; 2015; 10(11):e0142310. PubMed ID: 26562161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor antigen ROR1 targeted drug delivery mediated selective leukemic but not normal B-cell cytotoxicity in chronic lymphocytic leukemia.
    Mani R; Mao Y; Frissora FW; Chiang CL; Wang J; Zhao Y; Wu Y; Yu B; Yan R; Mo X; Yu L; Flynn J; Jones J; Andritsos L; Baskar S; Rader C; Phelps MA; Chen CS; Lee RJ; Byrd JC; Lee LJ; Muthusamy N
    Leukemia; 2015 Feb; 29(2):346-55. PubMed ID: 24947019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells.
    Daneshmanesh AH; Hojjat-Farsangi M; Khan AS; Jeddi-Tehrani M; Akhondi MM; Bayat AA; Ghods R; Mahmoudi AR; Hadavi R; Österborg A; Shokri F; Rabbani H; Mellstedt H
    Leukemia; 2012 Jun; 26(6):1348-55. PubMed ID: 22289919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.